Author
I. A. Asangani
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
Biology Disciplines
Click to filter author papersSignature Assays, Organisms & Methods
Click to filter · or open tagActivity by Year
2019-2023 · peak 1/yrCo-Author Collaboration Network
10 top collaborators · 24 mutual co-author links5 papers
Recent·Most cited
- Cancer BiologybioRxivPreprint
Setd2 inactivation sensitizes lung adenocarcinoma to inhibitors of oxidative respiration and mTORC1 signaling
D. M. Walter, A. C. Gladstein, K. R. Doerig…·D. M. Feldser
This study shows that SETD2 inactivation in lung adenocarcinoma leads to increased oxidative metabolism and mTORC1 activity, making these tumors sensitive to inhibitors of oxidative respiration and mTORC1.
DOI 10.1101/2022.10.06.511146 - Cancer BiologybioRxiv
Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1
Q. Deng, R. Natesan, F. Cidre-Aranaz…·i. a. asangani
The paper identifies a 32-gene signature specific to Ewing sarcoma and shows that LOXHD1, a stereociliary protein, is a key driver of malignancy through its regulation by EWSR1-FLI1.
DOI 10.1016/j.celrep.2022.110971 - Cancer BiologyBritish Journal of CancerPeer-reviewed
Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer
M. A. Siddiqui, P. N. Gollavilli, V. Ramesh…·P. Ceppi
This study identifies thymidylate synthase (TS) as a driver of epithelial-to-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC), linking it to metastasis, chemotherapy resistance, and survival.
DOI 10.1038/s41416-020-01095-x - Cancer BiologyCell Death & DifferentiationPeer-reviewed
Thymidylate synthase maintains the de-differentiated state of aggressive breast cancers
A. Siddiqui, P. N. Gollavilli, A. Schwab…·P. Ceppi
This study shows that thymidylate synthase promotes de-differentiation in aggressive breast cancers by supporting pyrimidine catabolism and EMT, correlating with poor prognosis.
DOI 10.1038/s41418-019-0289-6